Sulfadiazine Sodium Injection

Sulfonamides are the earliest type of artificially synthesized broad-spectrum antibacterial drugs used. The minimum effective concentration in the blood is 5 mg/100 ml, and 10-15 mg/100 ml is required for severe infections. They are effective against most Gram-positive bacteria and some Gram-negative bacteria. Sulfonamides exert their antibacterial effects by competing with PABA for dihydrofolate synthetase, hindering the synthesis of folate in sensitive bacteria. Sulfonamides have no effect on already synthesized folic acid, so the effect occurs slowly. Bacteria that can utilize exogenous folic acid are not sensitive to sulfonamides. Livestock and poultry cells can directly utilize folic acid, so they are not easily affected by sulfonamides blocking folic acid synthesis.

Sulfadiazine Sodium

This product is a colorless or slightly yellow clear liquid; it easily deteriorates when exposed to light.

This product is mainly used to treat patients with meningitis caused by sensitive Neisseria meningitidis. It can also be used to treat: 1. Acute bronchitis and mild pneumonia caused by Haemophilus influenzae, Streptococcus pneumoniae and other streptococci that are sensitive to it. 2. Astrocyte Nocardiosis. 3. An auxiliary drug for the treatment of chloroquine-resistant malignant malaria. 4. Combined with pyrimethamine to treat toxoplasmosis caused by Toxoplasma gondii.

This product needs to be diluted with sterile water for injection or saline to a 5% solution and slowly injected intravenously; the intravenous drip concentration is ≤1%. For the treatment of severe infections such as epidemic cerebrospinal meningitis, the intravenous dose for adults is 50 mg/kg for the first dose, followed by 100 mg/kg per day, divided into 3 to 4 intravenous drips or slow intravenous injections. For general infections in children over 2 months old, the dose of this product is 50 to 75 mg/kg per day, divided into 2 applications; the dose for epidemic cerebrospinal meningitis is 100 to 150 mg/kg per day, divided into 3 to 4 intravenous drips or slow intravenous injections.

1. Allergic reactions are relatively common. It can manifest as drug rash. In severe cases, exudative erythema multiforme, exfoliative dermatitis and bullous epidermolysis atrophic dermatitis may occur; there are also serum sickness-like reactions such as photosensitivity reaction, drug fever, joint and muscle pain, fever, etc. Anaphylactic shock is occasionally seen. 2. Neutropenia or deficiency, thrombocytopenia, and occasionally aplastic anemia. Patients may show symptoms of sore throat, fever and bleeding tendency. 3. Hemolytic anemia and hemoglobinuria. This is prone to occur in patients who lack glucose-6-phosphate dehydrogenase after using sulfonamides, and is more common in newborns and children than in adults. 4. Hyperbilirubinemia and neonatal kernicterus. Because this product competes with bilirubin for protein binding sites, it can cause an increase in free bilirubin. Newborns have imperfect liver function,

1. This product is contraindicated for those who are allergic to sulfonamide drugs. 2. This product is contraindicated for pregnant and lactating women. 3. This product is contraindicated for infants under 2 months old. 4. This product is contraindicated for those with liver and kidney damage.

1. Urine alkalinizing drugs can increase the solubility of this product in alkaline urine and increase excretion. 2. It cannot be used in combination with para-aminobenzoic acid, which can replace this product for bacterial uptake, and the two are antagonistic. 3. When the following drugs are used together with this product, this product can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action or toxic reactions. Therefore, when these drugs are used at the same time as this product, or when used after the application of this product, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium. 4. Combination with bone marrow suppressive drugs may enhance the adverse reactions of such drugs to the hematopoietic system. Such as leukopenia and thrombocytopenia, etc. If there is an indication for the use of the two drugs together, possible toxic reactions should be closely observed. 5. Long-term combination with contraceptives (estrogens) can reduce the reliability of contraception and increase the chance of extramenstrual bleeding. 6. When used in combination with thrombolytic drugs, their potential toxic effects may be increased. 7 When used in combination with hepatotoxic drugs, the incidence of hepatotoxicity may increase. Liver function should be monitored for such patients, especially those who have been taking the drug for a long time and have a history of liver disease. 8 When used in combination with photosensitive drugs, photosensitization may be additive. 9 Patients receiving this product have an increased need for vitamin K. 10 It should not be used in combination with methenamine, because methenamine can decompose in acidic urine to produce formaldehyde, which can form insoluble precipitates with this product. The risk of crystalluria increases. 11 This product can replace the plasma protein binding site of phenylbutazone, and when the two are used together, the effect of phenylbutazone can be enhanced. 12 When sulfinpyrazone is used in combination with this product, it can reduce the latter's secretion from the renal tubules, and its blood concentration increases and lasts for a long time, thereby producing toxic reactions. Therefore, the dose of this product may need to be adjusted during or after the application of sulfinpyrazone. When the course of sulfinpyrazone treatment is long, the blood concentration of this product should be monitored to help adjust the dose and ensure safe medication.

Keep away from light and store in sealed container.

5ml:1g

Shandong Xinhua Pharmaceutical Company Limited

• Founded in:

  1998-11-20

• Address:

  Chemical Industry Zone, Zibo High-tech Industrial Development Zone

• Tax NO.:

  91370300164103727C

• Registered Funds:

  682,407,635 yuan

• Website:

  Log in to view

• Email:

  Log in to view